Suffolk Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Suffolk Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-46,564	Closed	-$703K	–	151
2016 Q4	$703K	Buy	46,564 +2,709	+6%	+$38.3K	0.1%	126
2016 Q3	$668K	Sell	43,855 -16,899	-28%	-$683K	0.09%	128
2016 Q2	$2.36M	Sell	60,754 -278	-0.5%	-$9.99K	0.3%	101
2016 Q1	$1.7M	Buy	61,032 +30,527	+100%	+$1.02M	0.23%	122
2015 Q4	$1.64M	Buy	+30,505	New	+$1.54M	0.21%	126

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

HIM

Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

CCP

Clough Capital Partners Boston, Massachusetts $1.23B AUM 51.32% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

Suffolk Capital Management's ITCI Position: Q1 2017 in Review

Suffolk Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2017, closing a stake of 46,564 shares — an estimated $703K sold.

Suffolk Capital Management first reported a position in ITCI in Q4 2015 and held it in 5 quarters. The position peaked at $2.36M in Q2 2016. 117 funds tracked by Wall St. Rank hold ITCI as of Q1 2017.

Suffolk Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2017 after selling out during the quarter.
Suffolk Capital Management sold 46,564 Intra-Cellular Therapies Inc. shares in Q1 2017, an estimated $703K.
Suffolk Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q4 2015 and held it in 5 quarters.
Suffolk Capital Management's Intra-Cellular Therapies Inc. position peaked at $2.36M in Q2 2016.
117 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2017.

Based on Suffolk Capital Management's 13F filing for Q1 2017, filed 11 May 2017.